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Summary
Background: The complementarity determining region 3
(CDR3) of the immunoglobulin (Ig) heavy chain variable
region (VH) is the most reliable molecular fingerprint for most
if not all human B cells. The nucleotide sequence encoding for
any B-cell tumor-specific VH CDR3 is currently identified by
PCR sequencing based on procedures involving the usage of
either radioactive materials, patient/family-specific primers,
or bacterial cloning.
Patients and methods: In six consecutive patients with
follicular lymphoma we assessed the feasibility of a method
that allows for identification of the tumor-specific VH CDR3
using consensus primers while avoiding both radioactive ma-
terials and bacterial cloning procedures.
Results: The tumor-specific VH CDR3 was successfully
identified in all six patients in nearly half the time typically
required by any other method currently utilized. The feasibility
of the proposed method was not significantly affected either by
the tumor-specific Ig isotype, or by the tumor infiltration in the
original biopsy specimen. In the three patients for whom
tumor specimen-derived hybridomas were available, the tumor-
specific VH CDR3 was also found in at least 8 of 10 of them.
Conclusions: The proposed method allows the ability to
quickly identify the B-cell tumor-specific VH CDR3 using
consensus primers while avoiding radioactive materials and
bacterial cloning procedures.
Key words: CDR3. consensus primers, follicular lymphoma,
PCR, tumor-specific
Introduction
The nucleotide sequence encoding for the complemen-
tarity-determining region 3 (CDR3) of the human im-
munoglobulin (Ig) heavy chain variable region (VH) is
considered to be the best molecular fingerprint of any B
cell capable of synthesizing an Ig [1]. Several studies and
a number of applications are based on the elucidation of
the VH CDR3 nucleotide sequence, first and foremost
those related to anti-idiotype (Id) vaccination for B-cell
malignancies [2-4]. In fact, the identification of the
tumor-specific antigen, that is the tumor-associated,
Id-containing Ig, remains essential regardless of the
nature of the Id vaccine under construction: be it either
a soluble protein [5], Id-pulsed dendritic cells [6], or a
DNA sequence [7]. In this context, the certainty of such
identification relies on the sharp elucidation of the VH
CDR3 nucleotide sequence contained within the com-
plementary DNA (cDNA) sequence peculiarly encoding
for the whole tumor-specific VH. However, most B-cell
malignancy diagnostic samples typically contain a num-
ber of residual normal B cells. Each of these normal B
cells may be characterized by a different synthesized Ig
and, therefore, by a VH CDR3 nucleotide sequence that
is irrelevant to the tumor target and could hinder the
polymerase chain reaction (PCR)-based definition of
the VH CDR3 clonally featured by the tumor cells. In
particular, both genomic DNA and cDNA extracted
from lymphoma specimens contain a percentage of
tumor-specific, Ig-related VH CDR3 nucleotide sequen-
ces that depend on the percentage of clonal tumor cells
in the specimen.
Until now, the VH CDR3 nucleotide sequence has
been elucidated and/or monitored over time in a num-
ber of ways involving the use of either radiolabelled PCR
consensus primers [8-9], cloning techniques [10-12], or
patient-specific PCR primers [13-14]. Aside from the
obvious need to standardize the methodology used in
this process, we felt that the recent advent of the auto-
matic sequencers, together with the availability of reliable
PCR consensus primers might pave the way to develop-
ing a technique that avoids the use of both radioactive
materials and procedures involving bacterial cloning.
So far, the most refined and best described strategy to
elucidate the VH CDR3 nucleotide sequence was pub-
lished by Kobrin and Kwak in 1997 [8]. Again, it is
based on the use of either 32P- and/or 33P-labelled PCR
consensus primers.
* M.B. and R.T. contributed equally to this study.
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Patients and methods
Samples
Six relapsing FL patients underwent lymph node surgical biopsy as a
preliminary idiotype vaccination procedure pending diagnosis confir-
mation Indeed, one third of the lymph node was used for this purpose,
while the remaining two thirds were mechanically transformed in a
single cell suspension, aliquots of which were used for the molecular
analysis of the tumor-specific VH CDR3 nucleotide sequence.
Similarly, in the first three patients, hybridomas were produced
by fusing the same, both lymph node specimen-derived tumor and
normal cells with a heterohybridoma fusion partner (K6H6/B5). as
previously described [15]. Then, ten hybridomas per patient underwent
the same VH CDR3 nucleotide sequence molecular analysis as the
lymph node specimen-derived original cells.
V|( CDR3 sequencing and analysis
The amplified product was purified using the Qiaquick PCR purifica-
tion kit (Qiagen, Hilden, Germany), according to the manufacturer
instructions. Cycle sequencing was then performed using the BigDye
terminator kit (Perkin-Elmer. Foster City, California), according to
the manufacturer's standard procedures, and both the primers by
which the PCR product had been obtained. Automated sequencing
was carried out in the 377 ABI-PRISM sequencer (Perkin-Elmer,
Foster City, California).
The alignment of all the electropherograms obtained from PCR
products, based on the use of different couples of primers, was
performed using the Sequence Navigator software (Perkin-Elmer,
Foster City, California). Sequence analyses were finally carried out
utilizing the IgBLAST program at the NCBI web site (http://
www.ncbi.nlm.nih.gov/igblast).
V,,CDR3 isolation
Total RNA was extracted from both types of cell samples above, using
the RNeasy Mini Kit (Qiagen. Santa Clarita, California) according to
the manufacturer instructions. First-strand cDNA was then synthe-
sized using I ug of total RNA and the cDNA Synthesis Kit for RT-
PCR (Roche Diagnostics, Basel, Switzerland) according to the manu-
facturer's standard procedures. The synthesis was performed in a PTC
225 thermal cycler (MJ Research, Watertown, Massachusetts) at the
following temperatures: 25 °C for 10 minutes. 42 °C for 60 minutes and
99 °C for 5 minutes.
All PCRs were performed using 2.5 uls of cDNA. 50 ng of each
primer, 1 x Buffer II (purchased, like all the following PCR ingredients
from Perkin-Elmer, Foster City. California), 1.5 mM of MgCl2, 0.2
mM of each dNTP and 2 5 U of AmpliTaq Gold, in a final reaction
volume of 25 uls. The denaturation step was performed at 95 °C for 12
minutes, and was followed by 35 amplification cycles, each including
denaturation at 94 °C for 30 seconds, annealing at 53 °C for 30 seconds
and extension at 72 °C for 30 seconds. Finally, the conclusive extension
was performed at 72 °C for seven minutes.
Ten ul of the PCR final product were analyzed by electrophoresis in
a 1.5% agarose gel (FMC. Rockland, Maine), with 0.5 ug/ml of
ethidium bromide in 0 5 x TBE buffer (Gibco BRL. Basel. Switzer-
land). In a limited number of cases, the visualized band was not as
sharp as desired, but the problem was promptly solved by repeating the
electrophoresis step in 2.5% MetaPhor agarose gel (FMC, Rockland,
Maine), with 2 ug/ml ofethidium bromide in 1 x TBE buffer. The PCR
product-related band was then picked up by aspiration in a 10 ul tip cut
at the end and eluted overnight in 20 uls of the I x Buffer II above.
Four uls of the eluted PCR product were subsequently PCR re-
amplified using the same reagents above in terms of proportions, but in
a final reaction volume of 100 ul. The thermal cycler conditions were
also the same as above, except for the number of amplification cycles,
reduced to 20, and the annealing temperature, increased up to 60 °C.
Results
Elucidation of the VH CDR3 nucleotide sequence
In order to maintain in an unchanged manner as many
of their methodological improvements as possible, while
further refining, simplifying and modernizing the over-
all strategy, we decided to develop our system to eluci-
date the VH CDR3 nucleotide sequence using the very
same PCR primers currently used in Dr Kwak's labs at
the National Cancer Institute (Table 1). These primers
have been designed to anneal to highly-conserved re-
gions within framework regions (FR) 2, 3 and 4, as well
as to regions belonging to the heavy chain constant
region ( C H ) 1, consistent with the isotype of the anti-
body in question [16].
The cDNA obtained from the primary, diagnostic
lymph node specimen of six consecutive patients with
follicular lymphoma (FL) was used as a PCR template.
According to the designated consensus primer set
(Figure 1), and depending on the known isotype of the
tumor-associated Ig, a number of primer combinations
ranging from 4 to 10 per patient was used in the PCRs.
In particular, since typically not all primer combina-
tions yield a PCR product suitable for sequencing, the
number of combinations successfully used (Table 2),
was aimed at obtaining identical, confirmatory DNA
sequences from at least two fully-independent primer
combinations. Moreover, as a strict requirement, the
Table I. Primers used for VH fragment amplification.
FR2S1 5'-GATGAATTCGTCCTGCAGGC(CT)(CT)CCGG(AG)AA(AG)(AG)GTCTGGAGTGG-3'
FR2S2 5'-GATGAATTCTGG(AG)TCCG(AC)CAG(GC)C(CT)(CT)C(ATGC)GG-3'
FR3S1 5'-GATGAATTCACAC(AG)GC(CT)(ACG)(CT)(AG)TATTA(CT)TGT-3'
FR3S2 5'-GATGAATTCACACGGC(CT)(GC)TGTATTATTGT-3'
FR3S3 5'-GATGAATTCACACGGC(CT)(GC)TGTATTACTGT-3'
FR4ASI 5'-GACG(AG)TG(AG)CC(AG)(GT)GGT(AC)CCTTGGCCCCA-3'
CRM 5-CCAAGCTTAGACGACGGGGAAAAGGGTT-3'
CRG 5'-CCAAGCTTAGGG(CT)GCCAGGGGGAAGAC-3'
CRA 5'-GATAAGCTTGAGGCTCAGCGGGAAGACCTT-3'
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Figure 1 Schematic representation of PCR sense and anti-sense
consensus primers. CRM - u chain constant region anti-sense primer;
CRG - y chain constant region anti-sense primer; CRA - alpha chain
constant region anti-sense primer.
four individual primers constituting these two primer
combinations had to span different regions of the whole
tumor-specific heavy chain rearranged nucleotide se-
quence. These regions (Figure 1) are represented by the
FR2 and FR3 for the sense (S) primers (FR2S1, FR2S2,
FR3S1, FR3S2 and FR3S3 in Table 1) and by the FR4
and the CHI for the antisense (AS) primers (FR4AS1,
CRM, CRG and CRA in Table 1).
All patients' sequences were aligned using the Se-
quence Navigator software (Figure 2) and both their
full analysis and the identification of the matching VH
CDR3 nucleotide sequences were performed using the
IgBLAST program at the NCBI web site. Of course, the
length of all six patients' VH CDR3 nucleotide sequen-
ces fell within the known range of 2 to 26 aminoacids,
which is 6 to 78 nucleotides [8] (Table 2). In addition, the
number of non-clear-cut (N) nucleotides was remark-
ably low in all quality sequences (Figure 3), including
those obtained from short-length PCR products, which
classically tend to be mostly affected by reading difficul-
ties within the first 20-40 nucleotides when using dye
terminator cycle sequencing [17].
Concordance between rumor and tumor-derived
hybridoma VH CDR3
As further, indirect evidence for the tumor specificity of
each VH CDR3 nucleotide sequence identified by our
new method, we compared those elucidated, starting
from the primary diagnostic specimen, with those ob-
tained from the corresponding hybridomas, available for
the first three patients. The percentage of hybridomas
that originate from tumor cells rather than from residual
normal cells is always strictly dependent on the tumor
cell infiltration within the original biopsy specimen.
Therefore, the fact that at least 8 of 10 (Table 2) inde-
pendent, stochastically-fused hybridomas shared the ex-
pected VH CDR3 nucleotide sequence represents a fur-
ther demonstration of the accuracy of the new strategy.
The ability to identify the tumor-associated VH CDR3
nucleotide sequence is mantained, even as the tumor cell
infiltration within the diagnostic specimen falls as low as
50% (Table 2).
Result reproducibility regardless of tumor-specific Ig
isotype
A primary requirement for any method used to elucidate
tumor-specific VH CDR3 nucleotide sequences is repro-
ducibility, regardless of the corresponding Ig isotypes.
The lack of this feature would make the entire strategy
unreliable and consequently not routinely applicable,
particularly in the setting of both idiotype vaccination
[18] and minimal residual disease monitoring [19-20].
FL cells display a clonal igM on their surface in nearly
50% of cases, followed by IgG in most of the remaining
cases and only occasionally express IgA. Rarely, the
tumor cell express' no Ig on its surface [21]. Our method
accurately identified the tumor-associated VH CDR3
nucleotide sequence in all six patients; the tumor iso-
types were IgM in two cases, IgG in three cases, and IgA
Table 2. CDR3 nucleotide sequence of the six patients.
UPN Isotype NC CDR3 Sequence NH TI (%)
5'-GGGGAAGTGGGAGCGGAT-3' 9/10 60
5'-GGTATATATTTCTGTGCGATAGAGGGCGACGGTGACTCCCATTGGGGCCC 10/10 50
GGGGACT-3'
5'-TATGACGTCCGCCGACACGGGCGTTTATTATTGTGCGACHGGTCCCGGTCG 8/10 50
HGAATCCAATCG-31
5'-CTAAGATCGGAAGATACGGCTCGATATTTCGTTGCGGCCCAGAATGGGGGT NA 85
GGTCTTGATCCC-3'
5'-CTTAATTGTAGTAGTTGTCTACGGAATATGTTTAAGGGGTCTGGCTCGTACT NA 70
ATAAC-3'
5'-AAATTCCTCTGGGGATCCCCGTTATTCCTATTA-3' NA 75
Abbreviations: NC - number of primer combinations successfully utilized (see text); NH - number of hybridomas sharing the tumor-specific
CDR3 sequence; NA - not available; TI (%) - percentage of tumor infiltration in the diagnostic specimen.
1
2
3
4
5
6
IgM
IgM
IgA
IgG
IgG
IgG
6/10
3/6
2/4
4/4
2/4
3/4
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Figure 2. Alignment of IgBLAST program-analyzed nucleotide sequences all referring to a single, representative patient (patient no 1). All
CDR3s are underlined for better magnification. The asterisks indicate the primers used for sequencing.
in one case (Table 2). We can therefore surmise that the
CH consensus primers used in Dr Kwak's labs in a
radiolabelled-primer setting are similarly useful when
used in our procedure.
Discussion
From a conceptual standpoint, the difference between
elucidating the tumor-specific VH CDR3 nucleotide se-
quence from an agarose- [4, 9] rather than from a poly-
acrylamide- [8] extracted PCR product band might
appear small. Moreover, the former will contain a greater
number of lg VH CDR3 nucleotide sequences derived
from the whole diagnostic specimen, regardless of their
length, while the latter will only contain those sharing
the unique length corresponding to that of the tumor-
specific VH CDR3 nucleotide sequence [8]. In other
words, the former will be characterized by a definitely
higher degree of contamination due to irrelevant VH
CDR3 nucleotide sequences. In fact, due to the higher
resolution power characterizing the run of a PCR sample
on a polyacrylamide gel, the PCR product band ex-
tracted and purified from it contains only all VH CDR3
nucleotide sequences sharing the length of the tumor-
specific VH CDR3 [8]. On the contrary, most if not all
PCR product bands extracted and purified from various
types of agarose gel will contain at least some VH CDR3
nucleotide sequences characterized by a different length.
However, the method we have described here, based
on an agarose-extraction and purification of the PCR
product band, has yielded in a limited number of un-
selected patients an optimal rate of tumor-specific VH
CDR3 nucleotide sequence identifications in an easy
and reproducible way, while avoiding the use of radio-
active materials, patient specific primers, or bacterial
cloning procedures. This relatively new method appears
to make B-cell malignancy molecular fingerprinting less
labor-intensive and time-consuming (Table 3) regardless
of its applications, which include the monitoring of
minimal residual disease. Finally, in terms of procedure
impact on therapeutic strategies such as idiotype vacci-
nation, this method makes it easier to identify the
tumor-specific Ig, regardless of the subsequent use of
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Figure 3. VH CDR3 nucleotide electropherogram segments obtained from several primer combinations used for a single, representative patient
(patient no. I). The asterisks indicate the primers used for sequencing.
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this information and, therefore, of the nature of the
idiotype vaccine core.
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